Tallimustine
Tallimustine Basic information
- Product Name:
- Tallimustine
- Synonyms:
-
- Tallimustine
- FCE-24517
- N-[5-[[(3-Amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[4-[bis(2-chloroethyl)amino]benzoylamino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-1H-pyrrole-2-carboxamide
- Talimustine
- 1H-Pyrrole-2-carboxamide, N-[5-[[(3-amino-3-iminopropyl)amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-4-[[[4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methyl-1H-pyrrol-2-yl]carbonyl]amino]-1-methyl-
- Tallimustine USP/EP/BP
- CAS:
- 115308-98-0
- MF:
- C32H38Cl2N10O4
- MW:
- 697.61
- Mol File:
- 115308-98-0.mol
Tallimustine Usage And Synthesis
Uses
Tallimustine (FCE 24517), a distamycin-A derivative, is an anticancer agent[1][2][4].
in vivo
Tallimustine (3 mg/kg, i.p.) shows antileukaemic activity in L1210 tumor bearing mice[4].
Animal Model: | L1210 tumor bearing mice[2]. |
Dosage: | 3 mg/kg |
Administration: | Intraperitoneal injection (i.p.) |
Result: | Prolonged the survival of mice. |
References
[1] Herzig MC, et al. Tallimustine lesions in cellular DNA are AT sequence-specific but not region-specific. Biochemistry. 1999 Oct 19;38(42):14045-55. DOI:10.1021/bi991286r
[2] Bianchi N, et al. Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine. Br J Haematol. 2001 Jun;113(4):951-61. DOI:10.1046/j.1365-2141.2001.02843.x
[3] Erba E, et al. Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line. Int J Cancer. 1995 Jul 17;62(2):170-5. DOI:10.1002/ijc.2910620211
[4] Tagliabue G, et al. Combination of the new minor groove alkylator tallimustine and melphalan. Eur J Cancer. 1997 Feb;33(2):284-7. DOI:10.1016/s0959-8049(96)00435-2